Lexaria Bioscience Corp. LEXX Archives - Page 35 of 39

TuesdayOct 19, 2021 3:01 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules. The company is leveraging its drug delivery technology, DehydraTECH(TM), in the development of hypertension and anti-viral treatments — a big achievement already making an impact in the pharmaceutical industry. “Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far, it has proven useful for potentially treating hypertension, along with the delivery of colchicine, a drug with known SARS-CoV-2 anti-viral properties,” reads a recent article. “DehydraTECH is applied by incorporating an…

WednesdayOct 13, 2021 2:10 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its recent oral tetrahydrocannabinol (“THC”) absorption study THC-A21-1 revealed that DehydraTECH(TM)-THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. According to the update, DehydraTECH-THC delivered more THC into the bloodstream during the study than the industry standard medium chain triglyceride (“MCT” or “coconut oil”) based control formulation from the two-minute mark onwards, then dropped rapidly to the same level as the MCT control by the six-hour mark. “The…

TuesdayOct 12, 2021 1:25 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in the latest episode of the “Stock2Me Podcast,” an IBN (InvestorBrandNetwork) solution to provide specialized content distribution via widespread syndication channels. Lexaria’s CEO and Chairman Chris Bunka joined the latest episode to discuss the company’s business model, his professional background and the team behind Lexaria, as well as the company’s recent transformative steps to position it for accelerated growth. “Our company kind of had a rebirth in January 2021. … We completed a 1-for-30 reverse stock split,” Bunka explained. “That was really hard, and just…

FridayOct 08, 2021 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches

The company believes that the study findings support its patented DehydraTECH(TM) system as being the world’s fastest-acting nicotine through oral absorption and a safer nicotine alternative for the 1.1 billion smokers of the world Plans for a human trial are in the design process, and Lexaria intends to use existing capital to execute the study The global nicotine pouch market is expected to grow to a total revenue of $21.84 billion by the end of 2027, a CAGR growth of 30.7% over the forecast period A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) has announced the results…

TuesdayOct 05, 2021 1:17 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECH(TM)-nicotine delivered via the oral pouch product format required only two to four minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. In addition, DehydraTECH-nicotine reached statistically significant peak blood plasma levels up to 10-fold higher overall than controls (p=0.004) while still clearing from blood virtually as quickly as the controls. “We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral pouch formulations…

TuesdayOct 05, 2021 11:28 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage

Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery…

ThursdaySep 30, 2021 11:14 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as…

WednesdaySep 29, 2021 1:33 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats

Lexaria Bioscience Corp. (NASDAQ: LEXX), an innovator of drug delivery methods, is improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs with its patented technology. “DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro and human clinical testing,” reads a recent article. “The DehydraTECH technology is suitable for use with a wide range of product formats. These include pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (‘OTC’) capsules, pills, tablets, and oral suspensions. The technology was specifically designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients…

FridaySep 24, 2021 2:08 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) is making significant progress in advancing its patented DehydraTECH(TM) drug delivery technology. Lexaria recently reviewed its successful 2021 antiviral drug program. “The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish,” reads a recent article. In addition to the antiviral program, Lexaria is also focused on another applied R&D program — hypertension. On July 29, it released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for…

FridaySep 24, 2021 9:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery

One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments Since its inception, Lexaria Bioscience (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules in drugs. With its drug delivery technology, DehydraTECH(TM), the company has aided in developing hypertension and anti-viral treatments (https://ibn.fm/96k7t). This is a big achievement for…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX